Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Jan;67(1):205–210.

Endocytosis of particulate and soluble IgG immune complexes: differential effects of cytoskeletal modulating agents.

D S Finbloom, J Martin, R K Gordon
PMCID: PMC1542571  PMID: 3621675

Abstract

We determined the ability of cytoskeletal modulating agents to affect endocytosis of particulate and soluble immune complexes. Either immunoglobulin G-opsonized 51Cr-labelled erythrocytes (E) or 125I-labelled soluble IgG anti-dinitrophenyl immune complexes (IC) were added to adherent murine peritoneal macrophages and the extent of internalization was measured. Either intracellular 51Cr radioactivity or trichloroacetic acid soluble 125I radioactivity was monitored as an indication of uptake by the cell. In addition to cytochalasin B and colchicine, the phospholipid methylation inhibitors, 3-deazaadenosine and 3-deaza(+/-)aristeromycin, were used. Whereas incubation of macrophages with colchicine alone resulted in 50% inhibition of uptake of E-IgG, there was no effect on the degradation of soluble IC. Both cytochalasin B and colchicine produced a 95% inhibition of E-IgG uptake by macrophages, but these drugs only minimally inhibited (17%) the degradation of soluble immune complexes. Both inhibitors of methylation produced a 50% decrease in phospholipid methylation in treated cells. However, only 3-deazaadenosine inhibited phagocytosis (50% of control for E-IgG and 75% of control for soluble IC). These data suggest that an intact cytoskeleton is necessary for the uptake of a particulate immune complex and much less important for the internalization and degradation of these model soluble immune complexes. In addition, inhibition of phospholipid methylation reactions alone do not impare the uptake and degradation of either a soluble or a particulate immune complex.

Full text

PDF
205

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson J. P., Parker C. W. Modulation of macrophage Fc receptor function by cytochalasin-sensitive structures. Cell Immunol. 1977 Oct;33(2):353–363. doi: 10.1016/0008-8749(77)90164-2. [DOI] [PubMed] [Google Scholar]
  2. Cochrane C. G. Mechanisms involved in the deposition of immune complexes in tissues. J Exp Med. 1971 Sep 1;134(3 Pt 2):75s–89s. [PubMed] [Google Scholar]
  3. Finbloom D. S. Binding, endocytosis, and degradation of model immune complexes by murine macrophages at various levels of activation. Clin Immunol Immunopathol. 1985 Sep;36(3):275–288. doi: 10.1016/0090-1229(85)90048-0. [DOI] [PubMed] [Google Scholar]
  4. Finbloom D. S., Plotz P. H. Studies of reticuloendothelial function in the mouse with model immune complexes. I. Serum clearance and tissue uptake in normal C3H mice. J Immunol. 1979 Oct;123(4):1594–1599. [PubMed] [Google Scholar]
  5. Frank M. M., Hamburger M. I., Lawley T. J., Kimberly R. P., Plotz P. H. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med. 1979 Mar 8;300(10):518–523. doi: 10.1056/NEJM197903083001002. [DOI] [PubMed] [Google Scholar]
  6. Katayama S., Chia D., Knutson D. W., Barnett E. V. Decreased Fc receptor avidity and degradative function of monocytes from patients with systemic lupus erythematosus. J Immunol. 1983 Jul;131(1):217–222. [PubMed] [Google Scholar]
  7. Koffler D., Agnello V., Thoburn R., Kunkel H. G. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med. 1971 Sep 1;134(3 Pt 2):169s–179s. [PubMed] [Google Scholar]
  8. Leonard E. J., Skeel A., Chiang P. K., Cantoni G. L. The action of the adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine, on phagocytic function of mouse macrophages and human monocytes. Biochem Biophys Res Commun. 1978 Sep 14;84(1):102–109. doi: 10.1016/0006-291x(78)90269-3. [DOI] [PubMed] [Google Scholar]
  9. Leslie R. G. Macrophage handling of soluble immune complexes: evaluation of mechanisms involved in the selective clearance of complexes from the circulation. Mol Immunol. 1985 May;22(5):513–519. doi: 10.1016/0161-5890(85)90174-9. [DOI] [PubMed] [Google Scholar]
  10. Liotta L. A., Mandler R., Murano G., Katz D. A., Gordon R. K., Chiang P. K., Schiffmann E. Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A. 1986 May;83(10):3302–3306. doi: 10.1073/pnas.83.10.3302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. NIH conference. Pathophysiology of immune hemolytic anemia. Ann Intern Med. 1977 Aug;87(2):210–222. doi: 10.7326/0003-4819-87-2-210. [DOI] [PubMed] [Google Scholar]
  12. Plotz P. H., Kimberly R. P., Guyer R. L., Segal D. M. Stable model immune complexes produced by bivalent affinity labeling haptens: in-vivo survival. Mol Immunol. 1979 Sep;16(9):721–729. doi: 10.1016/0161-5890(79)90013-0. [DOI] [PubMed] [Google Scholar]
  13. Stopford C. R., Wolberg G., Prus K. L., Reynolds-Vaughn R., Zimmerman T. P. 3-Deazaadenosine-induced disorganization of macrophage microfilaments. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4060–4064. doi: 10.1073/pnas.82.12.4060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sung S. J., Silverstein S. C. Inhibition of macrophage phagocytosis by methylation inhibitors. Lack of correlation of protein carboxymethylation and phospholipid methylation with phagocytosis. J Biol Chem. 1985 Jan 10;260(1):546–554. [PubMed] [Google Scholar]
  15. Vogel S. N., Rosenstreich D. L. Defective Fc receptor-mediated phagocytosis in C3H/HeJ macrophages. I. Correction by lymphokine-induced stimulation. J Immunol. 1979 Dec;123(6):2842–2850. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES